Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland and premises in Ireland and USA. The Helsinn Group has been built on the basis of a unique business model, focused on the in- and out-licensing of pharmaceuticals and medical devices in therapeutic niche areas.

Helsinn in-licenses early to late stage new chemical entities, completes their development from the performance of preclinical and clinical studies and of chemistry, manufacturing and control (CMC) development, to the filing for and the attainment of their market approval world-wide. Then, the Group markets directly through its subsidiaries or out-licenses to its network of local pharmaceutical partners, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services.

The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn’s cGMP, ISO 14001 and OHSAS 18001 certified facilities in Switzerland and Ireland, and supplied worldwide to its customers.

Helsinn's business approach

Board of Directors and Top Management

News

Contacts